Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.

Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ.

Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):e1-5. doi: 10.1016/j.clml.2013.08.006. Epub 2013 Oct 26.

2.

Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.

Sanz J, Boluda JC, Martín C, González M, Ferrá C, Serrano D, de Heredia CD, Barrenetxea C, Martinez AM, Solano C, Sanz MA, Sanz GF; Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH).

Bone Marrow Transplant. 2012 Oct;47(10):1287-93. doi: 10.1038/bmt.2012.13. Epub 2012 Feb 13.

PMID:
22327127
3.
4.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2013 Jun;19(6):934-9. doi: 10.1016/j.bbmt.2013.03.009. Epub 2013 Mar 21.

5.

[Unrelated umbilical cord blood transplantation with TBI/Ara-c/CY non-ATG conditioning regimen for adults with hematologic malignancies].

Sun ZM, Liu HL, Geng LQ, Zhou CY, Wang XB, Ding KY, Tong J, Zhu WB, Liu X, Wang ZY.

Zhonghua Yi Xue Za Zhi. 2012 Jun 26;92(24):1660-4. Chinese.

PMID:
22944153
6.

Double-unit cord blood transplantation after myeloablative conditioning for patients with hematologic malignancies: a multicenter phase II study in Japan.

Kai S, Wake A, Okada M, Kurata M, Atsuta Y, Ishikawa J, Nakamae H, Aotsuka N, Kasai M, Misawa M, Taniguchi S, Kato S.

Biol Blood Marrow Transplant. 2013 May;19(5):812-9. doi: 10.1016/j.bbmt.2013.02.011. Epub 2013 Feb 14.

7.

Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.

van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Cheung T, Vijayakumar S, Hoffman R, Sosman J.

Bone Marrow Transplant. 2003 Jul;32(1):9-13.

PMID:
12815472
8.

Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.

Kato K, Yoshida N, Matsumoto K, Matsuyama T.

Pediatr Blood Cancer. 2014 Apr;61(4):712-6. doi: 10.1002/pbc.24922. Epub 2013 Dec 30.

PMID:
24376191
9.

[Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation].

Bautista G, Regidor C, Gonzalo-Daganzo R, Cabrera JR.

Methods Find Exp Clin Pharmacol. 2010 Dec;32 Suppl A:47-51. Spanish.

PMID:
21381288
10.

Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.

Okada M, Fujimori Y, Misawa M, Kai S, Nakajima T, Okikawa Y, Satake A, Itoi H, Takatsuka H, Itsukuma T, Nishioka K, Tamaki H, Ikegame K, Hara H, Ogawa H.

Biol Blood Marrow Transplant. 2008 Aug;14(8):896-903. doi: 10.1016/j.bbmt.2008.05.020.

11.

Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan.

Komatsu T, Narimatsu H, Yoshimi A, Kurita N, Kusakabe M, Hori A, Murashige N, Matsumura T, Kobayashi K, Yuji K, Tanaka Y, Kami M.

Ann Hematol. 2007 Jan;86(1):49-54. Epub 2006 Oct 12.

PMID:
17036221
12.

Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies.

Moscardó F, Sanz J, Senent L, Cantero S, de la Rubia J, Montesinos P, Planelles D, Lorenzo I, Cervera J, Palau J, Sanz MA, Sanz GF.

Haematologica. 2009 Jun;94(6):827-32. doi: 10.3324/haematol.2008.000935.

13.

Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313.

Pulsipher MA, Boucher KM, Wall D, Frangoul H, Duval M, Goyal RK, Shaw PJ, Haight AE, Grimley M, Grupp SA, Kletzel M, Kadota R.

Blood. 2009 Aug 13;114(7):1429-36. doi: 10.1182/blood-2009-01-196303. Epub 2009 Jun 15.

14.

Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.

Peterlin P, Delaunay J, Guillaume T, Gastinne T, Mahé B, Dubruille V, Blin N, Le Bourgeois A, Brissot E, Lodé L, Le Gouill S, Moreau P, Mohty M, Chevallier P.

Biol Blood Marrow Transplant. 2015 Jan;21(1):180-4. doi: 10.1016/j.bbmt.2014.08.018. Epub 2014 Aug 28.

15.

Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.

Markova M, Barker JN, Miller JS, Arora M, Wagner JE, Burns LJ, MacMillan ML, Douek D, DeFor T, Tan Y, Repka T, Blazar BR, Weisdorf DJ.

Bone Marrow Transplant. 2007 Feb;39(4):193-9. Epub 2007 Jan 15.

PMID:
17220905
16.

Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.

Ishida H, Adachi S, Hasegawa D, Okamoto Y, Goto H, Inagaki J, Inoue M, Koh K, Yabe H, Kawa K, Kato K, Atsuta Y, Kudo K.

Pediatr Blood Cancer. 2015 May;62(5):883-9. doi: 10.1002/pbc.25389. Epub 2014 Dec 24.

PMID:
25545836
17.

Rapid induction of single donor chimerism after double umbilical cord blood transplantation preceded by reduced intensity conditioning: results of the HOVON 106 phase II study.

Somers JA, Braakman E, van der Holt B, Petersen EJ, Marijt EW, Huisman C, Sintnicolaas K, Oudshoorn M, Groenendijk-Sijnke ME, Brand A, Cornelissen JJ.

Haematologica. 2014 Nov;99(11):1753-61. doi: 10.3324/haematol.2014.106690. Epub 2014 Aug 8.

18.

Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis.

Yamada MF, Miyamura K, Fujiwara T, Kohata K, Okitsu Y, Ohguchi H, Yamamoto J, Yokoyama H, Tomiya Y, Ishizawa K, Kameoka J, Harigae H.

Transplant Proc. 2008 Dec;40(10):3637-42. doi: 10.1016/j.transproceed.2008.06.102.

PMID:
19100456
19.

Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation.

Belkacémi Y, Labopin M, Hennequin C, Hoffstetter S, Mungai R, Wygoda M, Lundell M, Finke J, Aktinson C, Lorchel F, Durdux C, Basara N.

Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):544-51. Epub 2006 Dec 4.

PMID:
17141976
20.

Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen.

Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M, Fukuno K, Uchiyama M, Takasugi K, Iseki T, Tojo A, Yamaguchi T, Asano S.

Blood. 2007 Feb 1;109(3):1322-30. Epub 2006 Oct 12.

Supplemental Content

Support Center